Ovarian cancer is usually diagnosed at an advanced state, when it is hard to treat successfully. Death rates are high and progress toward new treatment has been slow.
The good news is that new information from genetic sequencing of high-grade serous ovarian cancers has revealed common weakness – mutations that cause defects in biological pathways that repair damaged DNA.
Our Team is focusing our efforts on this weakness – the existence of defects in DNA repair. By targeting DNA repair pathways, we hope to extend the use of existing treatments to more patients and to find combinations with available drugs that will be effective against ovarian cancer.